Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Item

http://www.wikidata.org/entity/Q36366636

Q36366636

about

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Minimal residual disease in acute myeloid leukaemia Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells Targeting cell cycle regulators in hematologic malignancies.Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.Comparative drug screening in NUT midline carcinoma.Recent Advances on Small-Molecule Survivin Inhibitors.Overview of CDK9 as a target in cancer research.Emerging cell cycle inhibitors for acute myeloid leukemia.Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.The rocky road to personalized medicine in acute myeloid leukaemia.Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.CDK9 inhibitors in acute myeloid leukemia.

P2860

Q24561485-1E984979-2F8B-40E2-8A7D-7A98B3879A60 Q28535342-C7D427B4-570D-4A08-AAA7-2EBD28AB0F16 Q33417803-007F2882-4596-4351-A75B-5FA2547C4E50 Q34179265-9CD41B4F-2C85-4AEE-A580-4A898631413F Q34773140-E3617567-9201-4A3D-9B6A-2CA0E5B38DAA Q35334436-E827B369-43EB-471D-B704-719DD1DCBFCC Q35698322-91F4F328-B83F-4F0D-A7AE-EA5A5B58E460 Q36002546-8BF45550-2033-41EB-BFF8-B5D1B59372C3 Q36015334-F0335EFB-4CA7-4D3A-A5D6-8C7D63D99875 Q36709001-298E54EF-CF8A-4D74-9F68-BA8FE120CB39 Q37632187-67F7162D-F8D6-48DB-A915-226974265ED1 Q37689286-29B4E3C1-1280-485C-8E31-5527EC70CFD1 Q38696353-413C72EC-D093-40F6-95D9-3B8AA6D57451 Q38785380-40363CD1-8FCE-4532-881E-84230FE5A6C8 Q38973410-27C97E36-8085-42F0-9F14-595648E392EA Q40079572-7D599D8B-B777-4FB8-AEF9-9D3EF166610F Q40926668-64C42256-FB0D-4C21-8F72-88A1309119EC Q42772353-96F16F00-CFB6-43DC-AF26-5AE9F901442D Q47561008-2CE3C859-EAF3-4C05-B7A1-0AA1C85B5F54 Q49840237-50F90346-6CC9-4D62-AC3D-C7BCA14EE412 Q50318294-81EF5142-3CE8-45A1-9C5C-B3F448725333

P2860

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Item

http://www.wikidata.org/entity/Q36366636

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@ast

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@en

type

Item

label

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@ast

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@en

prefLabel

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@ast

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@en

P1476

Randomized phase II study of t ...... sk acute myelogenous leukemia.

@en

P2093

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

D Michelle Drye

http://www.w3.org/2001/XMLSchema#string

Douglas E Gladstone

http://www.w3.org/2001/XMLSchema#string

Elihu H Estey

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Hetty E Carraway

http://www.w3.org/2001/XMLSchema#string

Jacqueline M Greer

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Cyclin-dependent kinase pathways as targets for cancer treatment

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

Preclinical and clinical development of cyclin-dependent kinase modulators.

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

P304

1736-1742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2012.062539

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Megan Othus

P577

2012-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228066279

http://www.w3.org/2001/XMLSchema#string

P698

22733022

http://www.w3.org/2001/XMLSchema#string

P932

3487449

http://www.w3.org/2001/XMLSchema#string

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

about

P2860

P2860

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932